For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
Tesamorelin
Growth Hormone Releasing Peptide
Dosage
Quantity
Price
$62.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- Tesamorelin 10mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
Summarizes published clinical and metabolic data from the tesamorelin development program (EGRIFTA) in HIV-associated lipodystrophy and related analyses. Educational only—does not replace FDA labeling or clinician judgment.
p = 0.005
Executive function
Significant cognitive score improvement reported in a subset analysis (trial-dependent endpoints).
18.2%
Visceral fat
Mean VAT reduction vs baseline at ~26 weeks in pooled Phase 3 HIV lipodystrophy trials.
117%
IGF-1 rise
Marked IGF-1 elevation versus baseline in monitored cohorts (lab-dependent).
37%
Hepatic fat
Liver fat fraction improvements at ~12 months in NAFLD substudies.
35%
NAFLD resolution
Complete fatty-liver resolution endpoint in a subset of responders.
Mechanism of action (review context)
GHRH receptor engagement
Synthetic GHRH analog binds pituitary GHRH receptors to restore pulsatile GH output with intact feedback loops.
IGF-1–linked lipolysis
Hepatic IGF-1 generation supports preferential visceral adipose loss while lean mass is largely preserved in trial narratives.
Metabolic remodeling
Ectopic fat reduction in liver and muscle correlates with improved insulin sensitivity markers without destabilizing mean glucose in many reports.
Differentiator vs exogenous GH: preserves endogenous pulsatile GH secretion rather than continuous pharmacologic GH exposure.
18.2%
Average visceral adipose reduction at 26 weeks
816 HIV-positive adults with lipodystrophy; primary endpoint = percent trunk fat (VAT) change by CT at 26 weeks vs placebo.
Consult FDA labels and primary trial manuscripts for full inclusion criteria.
Treatment outcomes
Responder and tolerability signals
VAT trajectory
Active drug vs placebo (illustrative)
IGF-1 axis
108–117%
Mean vs peak elevations vary by cohort and assay timing.
Triglycerides
−20
mg/dL-type reductions in VAT responders (range varies).
Lean mass
Preserved
No meaningful lean-tissue loss in pivotal narratives.
Body image
Improved
Patient-reported outcome shifts in QoL instruments.
Metabolic markers
Lipids & glucose
- Triglycerides↓ 20–50 mg/dL
- Total cholesterol↓ ~9 mg/dL
- Adiponectin↑ ~12%
- Fasting glucoseNo major mean shift
Muscle imaging
Density & cross-sectional area
- Trunk muscle density+4.86 HU
- Psoas cross-sectional area+0.46 cm²
- Rectus cross-sectional area+0.44 cm²
Absolute imaging units (not percent bars)—see trial imaging supplements.
Hepatic readouts
NAFLD / NASH signals
- Hepatic fat ↓ ~37% in substudy cohorts
- Fibrosis scores trend favorable in exploratory analyses
- Transcriptomic shifts toward reduced steatohepatitis risk
EGRIFTA remains the only FDA-approved therapy specifically for HIV-associated excess visceral adiposity with linked hepatic benefit discussions—verify current label indications.
Safety profile (Phase 3, n≈816)
GH-axis–related effects are expected and usually mild–moderate.
Injection site reactions
MildArthralgia
MildPeripheral edema
MildMyalgia
MildParesthesia
MildHypersensitivity
ModerateAnti-drug antibodies
Binding antibodies were detected in a subset yet did not blunt VAT loss or IGF-1 increments in aggregate analyses—clinical relevance judged low.
Discontinuation drivers
- Any AE-related stop8.8%
- GH-related events4.2%
- Injection reactions4.6%
- Serious AEs<4%
Most discontinuations clustered in the first 26 weeks.
Labeled warnings context
- Glucose intolerance / diabetes vigilance (~5% HbA1c ≥6.5% signal in summaries)
- Theoretical malignancy vigilance with sustained IGF-1 elevation
- Diabetic retinopathy progression risk in susceptible patients
- Fluid retention and edema in predisposed cohorts
Storage handling reference
Peptide handling
Cold chain
Follow manufacturer stability data.
Reconstitution
Sterile technique only.
Light
Protect from photodegradation.
Documentation
Log batch, date, and temperature.
Researcher notes
- Contraindicated with active malignancy per prescribing information—mirror that caution in any research plan.
- Use extra glycemic surveillance in patients with diabetes or prediabetes phenotypes.
- Monitor IGF-1 on a schedule aligned with investigator protocols and local regulations.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.